A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Immunovant, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 7,925 shares of IMVT stock, worth $218,016. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,925
Previous 7,925 -0.0%
Holding current value
$218,016
Previous $218,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$25.1 - $31.61 $125 - $158
-5 Reduced 0.06%
7,925 $209,000
Q1 2024

Apr 25, 2024

SELL
$30.27 - $43.79 $73,858 - $106,847
-2,440 Reduced 23.53%
7,930 $256,000
Q4 2023

Jan 30, 2024

BUY
$31.31 - $44.19 $29,775 - $42,024
951 Added 10.1%
10,370 $436,000
Q3 2023

Oct 25, 2023

SELL
$18.55 - $39.96 $5,212 - $11,228
-281 Reduced 2.9%
9,419 $361,000
Q2 2023

Aug 07, 2023

BUY
$14.2 - $23.75 $53,676 - $89,775
3,780 Added 63.85%
9,700 $184,000
Q1 2023

May 08, 2023

SELL
$15.27 - $19.72 $20,950 - $27,055
-1,372 Reduced 18.82%
5,920 $91,000
Q4 2022

Feb 01, 2023

SELL
$6.59 - $17.75 $5,166 - $13,916
-784 Reduced 9.71%
7,292 $129,000
Q1 2022

Apr 21, 2022

BUY
$5.06 - $8.77 $12,371 - $21,442
2,445 Added 43.42%
8,076 $44,000
Q4 2021

Feb 01, 2022

SELL
$7.33 - $9.32 $879 - $1,118
-120 Reduced 2.09%
5,631 $48,000
Q3 2021

Nov 15, 2021

SELL
$7.01 - $11.37 $42 - $68
-6 Reduced 0.1%
5,751 $50,000
Q2 2021

Jul 30, 2021

BUY
$9.4 - $16.85 $488 - $876
52 Added 0.91%
5,757 $61,000
Q1 2021

May 03, 2021

BUY
$13.08 - $49.6 $15,970 - $60,561
1,221 Added 27.23%
5,705 $92,000
Q4 2020

Jan 28, 2021

BUY
$36.36 - $52.71 $33,742 - $48,914
928 Added 26.1%
4,484 $207,000
Q3 2020

Nov 06, 2020

BUY
$22.61 - $38.9 $80,401 - $138,328
3,556 New
3,556 $125,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.